Live feed16:17:00·1443dPRReleasevia QuantisnowTheravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total ValueByQuantisnow·Wall Street's wire, on your screen.RPRX· Royalty Pharma plcTBPH· Theravance Biopharma Inc.Health Care
